The Drug Enforcement Administration (DEA) is seeking to drastically increase the amount of THC, ibogaine and psilocybin that’s manufactured for research purposes.
Ibogaine (top left), psilocybin (top right) and marijuana (bottom).
The DEA is seeking to almost double the amount of magic mushrooms and THC that’s produced to “support research and clinical trials”. The DEA is also proposing to almost quintuple the amount of ibogaine that’s produced, and to increase the amount of “other tetrahydrocannabinol” products by more than 2,200%.
The move by the DEA comes as congressional researchers say the agency is “likely” to reschedule marijuana to Schedule III, following a request from the Department of Health.
Specifically the DEA is requesting the production of psilocybin to be increased from 8,000 grams to 15,000 grams, while increasing production of psilocyn by around 12,000 to 24,000. They are requesting ibogaine production be increased from 30 grams to 150.
As for THC, the DEA is requesting an increase from 384,460 grams to 628,460.
The agency is retaining the 6.7 million-gram quota for marijuana.
The proposed increases from the DEA opens up a 30-day public comment period that is legally required before the changes can take effect.
“DEA is proposing increases.. for the following schedule I substances: all other tetrahydrocannabinol, delta-9-tetrahydrocannabinol, ibogaine, psilocybin, and psilocyn,” said the DEA in a post on the Federal Register. “These proposed increases are to support research and clinical trials by DEA-registered schedule I researchers. These proposed increases demonstrate DEA’s support for research with schedule I controlled substances.”
